Conditions: Brain Edema Brain Tumor
Keywords: peritumoral brain edema edema malignant brain tumor astrocytoma brain tumor dexamethasone Decadron
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 112
Healthy volunteers: no

Brief summary:
The purpose of this study is to examine the long-term safety and tolerability of human corticotropin-releasing factor (hCRF), XERECEPT®, in patients requiring dexamethasone (Decadron) to treat peritumoral brain edema. This open-label, extended-use study is open to all patients who participate in either of the blinded studies, NTI 0302, NTI 0303, or other designated studies, including patients who may have discontinued blinded study medication early but completed the protocol-stipulated follow-up periods.

Detailed description:
XERECEPT® is not a potential treatment for cancer, but may reduce the edema associated with tumors and as a result, decrease neurological symptoms.

Arms:
arm 1: All patients will receive hCRF (XERECEPT) 2mg/day

Interventions: intervention 1: hCRF [XERECEPT (corticorelin acetate injection)]
Intervention descriptions: intervention 1: 2mg/day

Protocol document: